Australia markets open in 2 hours 9 minutes

Gene Biotherapeutics, Inc. (CRXM)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
0.00000.0000 (0.00%)
At close: 03:22PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 6.49k
Enterprise value 881.11k
Trailing P/E 0.00
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)N/A
Enterprise value/revenue N/A
Enterprise value/EBITDA -1.49

Trading information

Stock price history

Beta (5Y monthly) 20.95
52-week change 30.00%
S&P500 52-week change 323.57%
52-week high 30.0001
52-week low 30.0000
50-day moving average 30.0001
200-day moving average 30.0001

Share statistics

Avg vol (3-month) 3N/A
Avg vol (10-day) 3N/A
Shares outstanding 564.93M
Implied shares outstanding 664.93M
Float 860.93M
% held by insiders 16.16%
% held by institutions 10.00%
Shares short (31 Dec 2013) 4150.25k
Short ratio (31 Dec 2013) 41.03
Short % of float (31 Dec 2013) 41.78%
Short % of shares outstanding (31 Dec 2013) 41.71%
Shares short (prior month 29 Nov 2013) 4448.45k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 21:20
Last split date 318 July 2013

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2020
Most-recent quarter (mrq)31 Dec 2020

Profitability

Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-261.90%
Return on equity (ttm)N/A

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -1.26M
Net income avi to common (ttm)-517.9k
Diluted EPS (ttm)-0.0200
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)386.03k
Total cash per share (mrq)0.01
Total debt (mrq)1.26M
Total debt/equity (mrq)N/A
Current ratio (mrq)0.08
Book value per share (mrq)-0.10

Cash flow statement

Operating cash flow (ttm)-1.13M
Levered free cash flow (ttm)-707.67k